Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Bayer
Age
18–45
Sex
MALE
Healthy volunteers
Accepted
You may be eligible if
Healthy male subject
Age: 18 to 45 years (inclusive) at the first screening examination / visit
Body mass index (BMI): 18.5 to 32 kg/m² (inclusive)
Ability to understand and follow study-related instructions. Subject, who is a sexually active man and has not been surgically sterilized, must consent that he uses a condom during intercourse and ensures that his female partner practices adequate contraception, or he must be willing to refrain from sexual intercourse from the beginning of the trial (signing of the informed consent) until 30 days after last study drug administration
You may not be if
Clinically significant disease or condition
Retinal pathology or vien occlusion
Left Ventricular ejection Fraction(LVEF) \<60% (as measured at screening) by Multiple Gated Acquisition Scan(MUGA) or echocardiogram
Clareo Health | Effect of Ketoconazole on the Pharmacokinetics of Refametinib
